Q-omics provides the consensus-scored FAM181A profile across patient tissues and cancer cell-line models. FAM181A expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM181A is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, FAM181A RNA expression shows 11,192 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where FAM181A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM181A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM181A survival associations across molecular data types. FAM181A RNA expression shows survival associations in the most cancer types (15), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM181A RNA expression–survival associations across cancer types. High FAM181A expression shows unfavorable associations in KIRC, LGG and COAD, but favorable associations in BRCA, SCLC and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM181A RNA expression.
This table summarizes FAM181A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM181A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM181A shows lower tumor expression in LUAD, LUSC, THCA, STAD, BRCA and PRAD. The LUAD box plot shows higher FAM181A RNA expression in normal versus tumor tissue (log2 FC = −1.783, t-test p < 0.001).
This table shows molecular features associated with FAM181A in patient tissues and cancer cell lines. In patient samples, FAM181A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM181A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and OVARY.
